Investor

Capital Royalty Group (CRG)

Healthcare investor providing debt and equity growth capital to healthcare companies worldwide

Write a review

Business
Partners
Partnership
Healthtech
+2 more

Visit Website Get introducedRequest an introduction Write a Review

Own this listing? Claim it

TrustList summary

Capital Royalty Group, or CRG, is a healthcare-focused investor that has supported industry growth since 2003. It provides growth capital to healthcare companies around the world.

The firm invests through debt and equity structures. It says it aims to limit dilution for its partners and to add value beyond funding.

What Capital Royalty Group offers

Debt financing: loan-style capital for healthcare businesses.
Equity investment: ownership stakes in healthcare companies.
Low-dilution structures: arrangements designed to keep founders' ownership high.
Partner support: collaborative working alongside the companies it funds.

Who it serves

Healthcare businesses seeking growth capital, and limited partners who invest in its funds and look for steady returns and protection against losses.

Key facts

Active since: 2003
Focus: global healthcare industry

Summary written by TrustList from the business's own published information, Oct 2026.

Gallery

2 images - click to enlarge

Categories & features

Business
Partners
Partnership
Healthtech
Biotech
New York City,

Rankings

Capital Royalty Group (CRG) is ranked on 3 TrustList rankings: #8 on 1, #15 on 1 and #18 on 1.

Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. Capital Royalty Group (CRG) has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.

Investor · 3 rankings

#8of 52
Biotech investors
It is one of 2 here listing partnership and one of 9 here listing partners.
Of the 52 here, 14 also cover seed stage and 14 also cover healthtech; 15 also work in Boston and 12 also work in New York City.
Behind Wellington Partners, ahead of RA Capital Management.
#15of 92
Healthtech investors
It is one of 11 here listing biotech.
Of the top 62 here, 17 also cover artificial intelligence and 13 also cover partners; 12 also work in London and 10 also work in San Francisco.
Behind OrbiMed, ahead of RA Capital Management.
#18of 157
New york city
It is one of 10 here listing healthtech.
Of the top 58 here, 8 also cover biotech and 7 also cover growth stage; 10 also work in Silicon Valley and 10 also work in Hong Kong.
Behind Kreos Capital, ahead of FinSight Ventures.